Bellerophon Therapeutics Inc

NASDAQ:BLPH   9:57:45 AM EDT
2.27
+0.09 (+4.13%)
Products, Regulatory

Bellerophon Reports Positive Top-Line Data From Phase 2 Acute Dose Escalation Study Of Inopulse For Treatment Of Pulmonary Hypertension Associated With Sarcoidosis

Published: 12/17/2021 13:53 GMT
Bellerophon Therapeutics Inc (BLPH) - Bellerophon Reports Positive Top-line Data From Phase 2 Acute Dose Escalation Study of Inopulse® for Treatment of Pulmonary Hypertension Associated With Sarcoidosis.
Bellerophon Therapeutics Inc - Phase 2 Results Provide Clinically Meaningful Reduction in Pulmonary Vascular Resistance.
Bellerophon Therapeutics Inc - Intends to Design Multi-dose Phase 2b Trial.
Bellerophon Therapeutics Inc - Treatment Was Safe and Well-tolerated.
Bellerophon Therapeutics Inc - No Treatment-emergent Adverse Events Observed During Acute Hemodynamic Dose Escalation Phase of Study.